GRO Biosciences is redefining therapeutics by leveraging new protein building blocks to transform treatment for countless patients. Their groundbreaking science expands the amino acid alphabet to deliver on the promise of protein-based therapies.
The company’s scientific teams, business teams, and founders are world-renowned pioneers with decades-long careers dedicated to genome engineering, computational biology, and therapeutic development. They are supported by investors with a proven track record of success in developing biotechnology platforms, commercializing novel therapies, and driving exponential growth in value. Their business team has closed over $2B in transactions.